Precision Probiotic Medicine to Improve ICB Immunotherapy
益生菌
可药性
免疫系统
免疫检查点
免疫疗法
人口
生物
肠道菌群
微生物学
计算生物学
作者
Blanda Di Luccia,Marco Colonna
出处
期刊:Cancer Discovery [American Association for Cancer Research] 日期:2022-05-02卷期号:12 (5): 1189-1190
标识
DOI:10.1158/2159-8290.cd-22-0221
摘要
Summary: The established impact of gut microbiota- and probiotic-derived metabolites on immune-checkpoint blockade (ICB) has spurred extensive efforts to identify strains and druggable bioactive molecules of microbial origin that can improve tumor immune therapy. In this issue, Kawanabe-Matsuda and colleagues show that the exopolysaccharide EPS-R1 produced by the probiotic strain Lactobacillus delbrueckii subsp. bulgaricus augments the response to ICB therapy by expanding the population of Peyer's patches CCR6+ CD8+ T cells, which can subsequently migrate from the gut into CCL20-expressing tumors to enhance antitumor activity. See related article by Kawanabe-Matsuda et al., p. 1336 (10).